20/20 Biolabs Inc (NASDAQ:AIDX) Sees Large Increase in Short Interest

20/20 Biolabs Inc (NASDAQ:AIDX) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totaling 291,990 shares, a growth of 126.7% from the May 31st total of 128,775 shares. Currently, 2.8% of the company’s shares are short sold. Based on an average trading volume of 2,692,121 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

A number of research firms have commented on AIDX. Maxim Group started coverage on 20/20 Biolabs in a research report on Monday, May 11th. They issued a “buy” rating and a $5.00 target price on the stock. Weiss Ratings initiated coverage on 20/20 Biolabs in a report on Thursday, May 14th. They set a “sell (e-)” rating for the company. Finally, Wall Street Zen raised 20/20 Biolabs to a “hold” rating in a research report on Saturday, March 14th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, 20/20 Biolabs has an average rating of “Hold” and a consensus price target of $5.00.

20/20 Biolabs Stock Performance

20/20 Biolabs stock traded down $0.03 during trading on Tuesday, hitting $0.57. The company had a trading volume of 54,938 shares, compared to its average volume of 652,326. 20/20 Biolabs has a 1-year low of $0.54 and a 1-year high of $50.00. The company has a 50 day simple moving average of $1.11.

20/20 Biolabs (NASDAQ:AIDX) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.28) EPS for the quarter. The business had revenue of $0.35 million during the quarter.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.